This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Biotinylated Human 4-1BB / TNFRSF9 Protein, Avitag™,His Tag
catalog :
41B-H82E3
quantity :
200 ug, 25 ug
price :
1380 USD, 350 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
41B-H82E3
product name :
Biotinylated Human 4-1BB / TNFRSF9 Protein, Avitag™,His Tag
quantity :
200 ug, 25 ug
price :
1380 USD, 350 USD
quantity & price :
$350/25ug,$1380/200ug
target :
4-1BB
host species :
Human
By Tag :
His Tag & Avi Tag
Research :
For Research Use Only
Source :
Biotinylated Human 4-1BB, Avitag,His Tag (41B-H82E3) is expressed from human 293 cells (HEK293). It contains AA Leu 24 - Gln 186 (Accession # NP_001552.2).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>90% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Biotinylated Human 4-1BB, Avitag,His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.
References :
(1)Cooper D, et al., 2002, Eur. J. Immunol. 32 (2): 521–9.
(2)Jang, I K., et al., 1998, Biochem. Biophys. Res. Commun. (UNITED STATES) 242 (3): 613–20.
(3)Arch, R H., Thompson C B., 1998, Mol. Cell. Biol. (UNITED STATES) 18 (1): 558–65.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics. The company employs an application oriented development strategy, with a particular focus on product design, quality control and solution based support. Our products and services enable anyone in the field of drug development to have a more intuitive and streamlined process. We have multiple offices and branches in North America, Europe, and Asia, and we are proud of serving customers from over 50 countries.
questions and comments